The three products compared here are sold under the BPC-157 name
BPC-157 (Body Protection Compound-157), a synthetic gastric peptide analogue, and Thymosin Beta-4, an actin-sequestering protein fragment, demonstrate mechanisms of action directly relevant to the vascular and connective tissue dysfunction underlying chronic hemorrhoids
No adverse effects have been reported with intake of normal daily requirements during lactation
See additional research at PubMed BPC-157 research
18(2):185 Multifunctionality and possible medical application of the BPC 157 peptide: literature and patent review Bock-Marquette I, Maar K, Maar S, Lippai B, Faskerti G, Gallyas F Jr, Olson EN, Srivastava D., International Immunopharmacology , 2023
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)